Satraplatin

This classification denotes a platinum compound with the molecular formula C6H13N.2C2H3O2.2Cl.Pt.H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8D7B37T28G, chemically known as platinum, bis(acetato-o)amminedichloro(cyclohexanamine)-, (oc-6-43)- but more generally known as satraplatin, which bears US NIH Compound Identifier 123974. European Medicines Agency schedules Satraplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04333MIG. The term SATRAPLATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules satraplatin in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SATRAPLATIN remains US FDA's Preferred Term for this commodity. Satraplatin bears US NLM identifiers UMLS ID C1142934 and NCI Concept Code C1493. Most nations, for tariff and trade purposes, schedule satraplatin under HS 28439090 and SITC 52432. SMILES: CC(=O)[O-].CC(=O)[O-].C1CCC(CC1)N.N.[Cl-].[Cl-].[Pt+4].